Kommunikation der Kirche - Kirche der Kommunikation

Christlicher Glaube ist Kommunikation. Das ist doch das doppelt Aufregende an ihm: Im Blick auf Gott gesagt: - Er ist das Gegenteil einer bloßen Theorie über Gott, er ist die Überzeugung, daß Gott selber an uns handelt, daß er unmittelbar zu uns ist und daß wir unmittelbar sind zu ihm, wir zu ihm reden dürfen, er uns hört, er auf uns eingeht, ja er in seinem menschgewordenen Sohn, in seinem Kreuz an uns leidet. Und in der anderen Richtung ist solcher Glaube - so sehr er die Entscheidung des Einzelnen ist, die ihm durch keine Institution, keine Gruppe, keinen objektiven Mechanismus abgenommen werden kann - nie einsamer Glaube, sondern in seiner Vermittlung und in seinem Vollzug angewiesen aufs Wir. (...)EnglishChristian faith is communication. Faith either communicates itself, or it is not true faith. The possibility of man's unlimited communication is one of the objectives of the Christian faith, which teaches man's perfectibility in the "communio sanctorum". Certain consequences of this truth arise for the future of the Church: 1. Christian witness has to express itself in communications media also, and the Church needs the media to proclaim the Good News to all men. 2. The Church cannot rely exclusively on the public communications media. Personta-person communication in the parish and in small groups is indispensible. 3. The Church, through the media, can help towards direct encounter in a small group and lead to dialogue. 4. Man must also have the right to, and the environment for non-communication. He must not be exposed to total communication, either as subject or as object. 5. The Church of tomorrow has to facilitate communication and qualify as a communicator on ail levels. 6. The Church, by reason of its catholicity, has to foster communication among ail men and bring distinct cultures into a world communication. 7. The content of Christian faith is essentiaily communication: there is communication in God himself. The exercise of Christian faith has always to show its power of communication. The age of communication needs a Theology of Communication to bring to light the core of the message

Das Zentralkomitee der deutschen Katholiken und die Diözesen

[Abstract fehlt

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

Natural killer (NK) cells are key effectors in cancer immunosurveillance and posttransplant immunity, but deficiency of environmental signals and insufficient tumor recognition may limit their activity. We hypothesized that the antibody-mediated anchoring of interleukin-2 (IL-2) to a spliced isoform of the extracellular matrix (ECM) glycoprotein tenascin-C would potentiate NK-cell–mediated antibody-dependent cellular cytotoxicity against leukemic blasts. In this novel-novel combination, dose-escalation, phase 1 trial, we enrolled patients with posttransplant acute myeloid leukemia (AML) relapse to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary activity of the antibody-cytokine fusion F16IL2 (10 3 106 to 20 3 106 IU IV; days 1, 8, 15, and 22 of each 28-day cycle) in combination with the anti-CD33 antibody BI 836858 (10-40 mg IV, 2 days after each F16IL2 infusion). Among the 15 patients (median [range] age, 50 [20-68] years) treated across 4 dose levels (DLs), 6 (40%) had received 2 or 3 prior transplantations. The most frequent adverse events were pyrexia, chills, and infusion-related reactions, which were manageable, transient and of grade #2. One dose-limiting toxicity occurred at each of DLs 3 (pulmonary edema) and 4 (graft-versus-host disease). Three objective responses were observed among 7 patients treated at the 2 higher DLs, whereas no responses occurred at the 2 starting DLs. Combination therapy stimulated the expansion and activation of NK cells, including those expressing the FcgRIIIA/CD16 receptor. ECM-targeted IL-2 combined with anti-CD33 immunotherapy represents an innovative approach associated with acceptable safety and encouraging biologic and clinical activity in posttransplant AML relapse. This trial was registered at EudraCT as 2015-004763-37